头颈癌颌下腺保护放疗中颌下腺功能的定量99mTc-高锝酸盐闪烁显像评估:前瞻性纵向研究
该前瞻性纵向研究纳入接受根治性容积旋转调强放疗的头颈鳞癌成人患者,用动态99mTc-高锝酸盐闪烁显像评估颌下腺保护对唾液功能的影响。共113例入组,27例颌下腺保护与53例未保护患者有闪烁显像数据。保护组在12个月时最大摄取恢复更显著(81.2 cps vs 54.8 cps,p=0.035),各时间点唾液排泄分数均显著更高(p<0.01),且保护腺周围无复发。结论认为颌下腺保护安全且能显著减少放疗所致唾液功能障碍。
要点
- 颌下腺保护组12个月最大摄取恢复显著优于未保护组(81.2 cps vs 54.8 cps,p=0.035)。
- 保护组3、6、12个月唾液排泄分数均显著高于未保护组(p<0.01)。
- 保护腺周围研究期间无复发,提示颌下腺保护安全。
核心结论
- 颌下腺保护放疗安全,且能显著减少放疗诱导的唾液功能障碍。
- 动态99mTc-高锝酸盐闪烁显像是评估腺体功能的可靠、微创方法。
研究设计与样本
- 前瞻性纵向研究,招募计划接受根治性容积旋转调强放疗的头颈鳞状细胞癌成人患者。
- 于基线及放疗后3、6、12个月行99mTc-高锝酸盐闪烁显像,计算最大摄取、唾液排泄分数、唾液排泄分数相对变化及唾液排泄分数比值。
- 2022年6月至2024年1月共招募113例,其中27例颌下腺保护与53例未保护患者有闪烁显像数据。
主要发现
- 基线平均最大摄取保护组82.7 cps vs 未保护组81.5 cps;3个月下降至66.5 cps vs 72.7 cps。
- 12个月保护组最大摄取恢复至81.2 cps,未保护组为54.8 cps(p=0.035)。
- 3、6、12个月唾液排泄分数保护组分别为27.6(IQR 19.6-42.1)、23.9(IQR 17.7-31.2)、29.9(IQR 18.3-34.7),未保护组分别为2.8(IQR -2.9-6.9)、4.4(IQR 1.8-9.1)、5.8(IQR 2.6-7.6),各时间点p<0.01。
- 3、6、12个月保护组保留功能分别为78.5%、89.6%、87.0%,未保护组分别为10.5%、17.4%、14.0%(各时间点p<0.01)。
- 研究期间保护腺周围无复发。
临床怎么用
- 头颈癌根治性放疗计划中可考虑保护颌下腺,以保留唾液功能。
- 动态99mTc-高锝酸盐闪烁显像可作为纵向评估颌下腺功能的微创工具。
局限性
- 113例招募中仅27例保护组和53例未保护组有可用的闪烁显像数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study evaluates the efficacy of submandibular gland sparing radiotherapy in reducing salivary dysfunction using dynamic 99mTechnetium pertechnetate scintigraphy. MATERIALS AND METHODS: Adults with head and neck squamous cell carcinoma planned for radical radiation using volumetric modulated arc radiotherapy were recruited in the study. The salivary function was assessed using 99mTechnetium pertechnetate scintigraphy at baseline, 3-, 6-, and 12 months post-radiation. Maximum Uptake (Umax), Salivary Excretion Fraction (SEF), relative change in SEF (rSEF), and SEF ratio were calculated and compared at different time points. RESULTS: Between June 2022 and January 2024, 113 patients were recruited, with scintigraphy data available for 27 patients with spared and 53 with unspared submandibular glands. At baseline, the mean Umax was 82.7 counts/second (cps) (spared) versus 81.5 cps (unspared). There was a decline at 3 months (66.5 cps vs. 72.7 cps), with significantly greater recovery by 12 months in the spared glands (81.2 cps vs. 54.8 cps; p = 0.035). SEF values at 3, 6, and 12 months respectively were 27.6 (IQR 19.6-42.1), 23.9 (IQR 17.7-31.2), and 29.9 (IQR 18.3-34.7) in spared glands compared to 2.8 (IQR -2.9-6.9), 4.4 (IQR 1.8-9.1), and 5.8 (IQR 2.6-7.6; p < 0.01 at all timepoints) in the unspared glands. At 3, 6, and 12 months, spared glands retained 78.5 %, 89.6 %, and 87.0 % function, compared to 10.5 %, 17.4 %, and 14.0 % in unspared glands (p < 0.01 at all time points). No recurrences occurred near the spared glands during the study period. CONCLUSION: Submandibular gland sparing is safe and significantly reduces radiation-induced salivary dysfunction. Dynamic 99mTc-pertechnetate scintigraphy is a reliable, minimally invasive method for evaluating gland function.
引用
- Garg P, Shyama Prem S, Ponnusamy M, et al. Evaluation of submandibular gland function using quantitative 99mTc-pertechnetate scintigraphy in submandibular gland sparing radiotherapy for head-neck cancers, a prospective longitudinal study. Clin Transl Radiat Oncol. 2025. PMID: 41281628. doi:10.1016/j.ctro.2025.101066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。